共 36 条
Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study
被引:15
作者:
Hawley, Samuel
[1
]
Javaid, M. Kassim
[1
,2
]
Rubin, Katrine H.
[3
]
Judge, Andrew
[1
,2
]
Arden, Nigel K.
[1
,2
]
Vestergaard, Peter
[4
,5
]
Eastell, Richard
[6
]
Diez-Perez, Adolfo
[7
,8
]
Cooper, Cyrus
[1
,2
]
Abrahamsen, Bo
[3
,9
]
Prieto-Alhambra, Daniel
[1
,2
,7
,8
,10
]
机构:
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Musculoskeletal Biomed Res Unit, Oxford Natl Inst Hlth Res NIHR, Oxford, England
[2] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England
[3] Univ Southern Denmark, Inst Clin Res, Odense Patient Data Explorat Network OPEN, Odense, Denmark
[4] Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark
[5] Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark
[6] Univ Sheffield, Dept Human Metab, Sheffield, S Yorkshire, England
[7] Univ Autonoma Barcelona, Hosp del Mar Med Res Inst IMIM, E-08193 Barcelona, Spain
[8] Inst Salud Carlos III, Red Temat Invest Cooperat Envejecimiento & Fragil, Barcelona, Spain
[9] Glostrup Cty Hosp, Res Ctr Ageing & Osteoporosis, Glostrup, Denmark
[10] Univ Autonoma Barcelona, Jordi Gol Primary Care Res Inst, Inst Invest Atencio Primaria IDIAP, Grp Recerca Malalties Prevalents Aparell Locomoto, E-08193 Barcelona, Spain
基金:
英国医学研究理事会;
关键词:
OSTEOPOROSIS;
BISPHOSPHONATES;
TREATMENT FAILURE;
EPIDEMIOLOGY;
FRACTURES;
POSTMENOPAUSAL WOMEN;
TREATMENT FAILURE;
OSTEOPOROSIS TREATMENT;
ZOLEDRONIC ACID;
RISK-FACTORS;
HEALTH-CARE;
ALENDRONATE;
PERSISTENCE;
THERAPY;
MEDICATION;
D O I:
10.1002/jbmr.2595
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Oral bisphosphonates (BPs) are highly effective in preventing fractures and are recommended first-line therapies for patients with osteoporosis. We identified the incidence and predictors of oral BP treatment failure, defined as the incidence of two or more fractures while on treatment (>= 2 FWOT) among users with high adherence. Fractures were considered from 6 months after treatment initiation and up to 6 months after discontinuation. Data from computerized records and pharmacy invoices were obtained from Sistema d`Informacio per al Desenvolupament de l`Investigacio en Atencio Primaria (SIDIAP; Catalonia, Spain) and Danish Health Registries (Denmark) for all incident users of oral BPs in 2006-2007 and 2000-2001, respectively. Fine and Gray survival models using backwardstepwise selection (p-entry 0.049; p- exit 0.10) and accounting for the competing risk of therapy cessation were used to identify predictors of >= 2 FWOT among patients having persisted with treatment >= 6 months with overall medication possession ratio (MPR) >= 80%. Incidence of >= 2 FWOT was 2.4 (95% confidence interval [CI], 1.8 to 3.2) and 1.7 (95% CI, 1.2 to 2.2) per 1000 patient-years (PYs) within Catalonia and Denmark, respectively. Older age was predictive of >= 2 FWOT in both Catalonian and Danish cohorts: subhazard ratio (SHR) = 2.28 (95% CI, 1.11 to 4.68) and SHR = 2.61 (95% CI, 0.98 to 6.95), respectively, for 65 to < 80 years; and SHR = 3.19 (95% CI, 1.33 to 7.69) and SHR = 4.88 (95% CI, 1.74 to 13.7), respectively, for >= 80 years. Further significant predictors of >= 2 FWOT identified within only one cohort were dementia, SHR = 4.46 (95% CI, 1.02 to 19.4) (SIDIAP); and history of recent or older fracture, SHR = 3.40 (95% CI, 1.50 to 7.68) and SHR = 2.08 (95% CI: 1.04-4.15), respectively (Denmark). Even among highly adherent users of oral BP therapy, a minority sustain multiple fractures while on treatment. Older age was predictive of increased risk within both study populations, as was history of recent/old fracture and dementia within one but not both populations. Additional and/or alternative strategies should be investigated for these patients. (c) 2015 American Society for Bone and Mineral Research.
引用
收藏
页码:234 / 244
页数:11
相关论文